Solfy Tablets 5Mg

Brand : sami pharm (pvt) ltd.

Rs. 565.30

Rs. 595.01

|

QUICK DELIVERY

Solfy Tablets Specification

Requires Prescription (YES/NO)

Yes

Generics

Solifenacin Succinate

Used For

Frequent Urination

How it works

Solifenacin is a competitive, specific cholinergic-receptor antagonist.The urinary bladder is innervated by parasympathetic cholinergic nerves . Acetylcholine contracts the detrusor smooth muscle through muscarinic receptors of which the M3 subtype is predominantly involved. Solifenacin is a competitive inhibitor of the muscarinic M3 subtype receptor.

Solfy Tablets Usage And Safety

Dosage

Solifenacin Succinate

Side Effects

Very common Dry mouth.Common Constipation, nausea, dyspepsia, abdominal pain, blurred vision.Uncommon : Gastroesophageal reflux diseases, dry throat, urinary tract infection, cystitis, somnolence, dysgeusia, dry eyes, fatigue, peripheral edema, nasal dryness, dry skin, difficulty in micturation.Rare : Colonic obstruction, fecal impaction, urinary retention.

Drug Interactions

Metoclopramide , cisapride , Ketoconazole and other CYP3A4 Inhibitors , CYP3A4 substrates with higher affinity (e.g., verapamil, diltiazem) and CYP3A4 inducers (e.g., rifampacin, phenytoin, carbamazepin).

Indication

Solifenacin Succinate is indicated for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

When not to Use

Solifenacin Succinate is contraindicated in patients with: - Hypersensitivity to the active substance or to any of the excipients.- Urinary retention. - Gastric retention.- Uncontrolled narrow-angle glaucoma. - Patients undergoing hemodialysis.- Patients with severe hepatic insufficiency and renal insufficiency . Solifenacin Succinate should not be used in children as safety and efficacy in children have not yet been established.

Solfy Tablets Precautions

Precaution

Angioedema of the face, lips, tongue, and/or larynx may occur after the first dose. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, solifenacin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.

Solfy Tablets Warnings

Warning 1

Solifenacin Succinate should be used with caution in patients with clinically significant bladder outflow obstruction at risk of urinary retention.

Warning 2

Solifenacin Succinate should be used with caution in patients with severe renal impairment (Clcr 30 mL/min and doses should not exceed 5mg for these patients. Moderate hepatic insufficiency and doses should not exceed 5mg for these patients.

Warning 3

Solifenacin Succinate should be used with caution in patients with hiatus hernia/gastroesophageal reflux and/or who are concurrently taking medicinal products (such as bisphosphonates) that can cause or exacerbate oesophagitis.